PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Leflunomide - Respiratory disease indications

PAD Profile : Leflunomide - Respiratory disease indications

Keywords :
RMOC, national shared Care, Interstitial Lung Disease (off label)
Brand Names Include :
Arava

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications

03 May 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approve the RMOC national shared care protocol with ‘local adaptations.

The local adaptation is:

Specialist Responsibilities

  • The initiating specialist will be expected to initiate and optimise treatment and prescribe the maintenance treatment for at least 12 weeks and until optimised.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More